Sanjay Kaul

TL;DR: Bleeding complications have been associated with an increased risk of subsequent adverse outcomes, including MI, stroke, stent thrombosis, and death, in patients with ACS and in those undergoing percutaneous coronary intervention (PCI) as well as in the long-term antithrombotic setting.

TL;DR: The term "vulnerable patient" may be more appropriate and is proposed now for the identification of subjects with high likelihood of developing cardiac events in the near future and a quantitative method for cumulative risk assessment of vulnerable patients needs to be developed.

TL;DR: Those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes.

TL;DR: The American College of Cardiology Foundation (ACCF) Task Force on Clinical Expert Consensus Documents (ECDs) as mentioned in this paper developed by the ACCF and other cosponsors are intended to inform practitioners, payers, and other interested parties of the opinion of the ACC and document cosponsors concerning evolving areas of clinical practice and/or technologies that are widely available or new to the practice community.

TL;DR: The reader should view the expert consensus document as the best attempt of the ACCF and document cosponsors to inform and guide clinical practice in areas where rigorous evidence may not yet be available or evidence to date is not widely applied to clinical practice.